Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in ...
Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% ORR at 12 mg/kg in pretreated ES-SCLC patients, selected as optimal dose for IDeate-Lung01 phase 2 trial extension and IDeate-Lung02 phase 3 study.
Related Clinical Trials
Reference News
IDeate-Lung01 study interim analysis shows ifinatamab deruxtecan (I-DXd) at 12 mg/kg has 54.8% confirmed objective response rate (ORR) in extensive-stage small cell lung cancer (SCLC), significantly higher than 8 mg/kg dose (26.1% ORR). Higher dose also shows better disease control rate and intracranial activity.
Merck & Co. and Daiichi Sankyo report 54.8% objective response rate with ifinatamab deruxtecan in pretreated ES-SCLC patients, selecting 12 mg/kg dose for Phase 2 and 3 trials.
Ifinatamab deruxtecan shows promising objective response rates in pretreated extensive-stage small cell lung cancer patients in the IDeate-Lung01 phase 2 trial, with confirmed ORR of 54.8% and 26.1% in 12 mg/kg and 8 mg/kg cohorts, respectively.
Daiichi Sankyo and Merck's antibody-drug conjugate, patritumab deruxtecan, met Phase 3 trial goals, delaying EGFR-mutated non-small cell lung cancer progression better than chemotherapy. The drug uses an antibody to target tumor cells and release a toxic chemical. Daiichi has six ADCs using deruxtecan chemotherapy, including Enhertu, with sales of $1.8 billion in H1 2024. Merck's $22 billion deal with Daiichi aims to bolster its pipeline as Keytruda patents near expiration.
Daiichi Sankyo and MSD report Phase III HERTHENA-Lung02 trial of patritumab deruxtecan met primary endpoint of progression-free survival in EGFR-mutated NSCLC patients. The trial showed a significant PFS improvement for patritumab deruxtecan versus chemotherapy, with a safety profile consistent with previous studies.
Ifinatamab deruxtecan (I-DXd) showed improved efficacy in heavily pretreated extensive-stage small cell lung cancer (ES-SCLC) patients, with a 12-mg/kg dose achieving a 54.8% overall response rate (ORR) vs 26.1% for an 8-mg/kg dose. The 12-mg/kg dose also had a 90.5% disease control rate (DCR) and a median duration of response (DOR) of 4.2 months, compared to 7.9 months for the 8-mg/kg dose. Both doses were generally well-tolerated, with gastrointestinal and hematologic toxicities as the primary adverse effects.
Merck & Co and Daiichi Sankyo's late-stage trial of patritumab deruxtecan in EGFR-mutated NSCLC met primary endpoint of PFS, showing significant improvement over standard chemotherapy. The trial continues to assess overall survival, with plans to discuss findings with regulatory authorities.
Merck and Daiichi Sankyo's patritumab deruxtecan met primary endpoint in Phase III HERTHENA-Lung02 study for EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival. Safety profile consistent with prior studies, though two grade 5 interstitial lung disease deaths occurred. Full results to be presented at a medical meeting.
Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% objective response rate at 12 mg/kg in pretreated extensive-stage small cell lung cancer patients, leading to its selection for phase 2 and 3 trials.
IMFINZI is indicated for various lung cancer treatments, including unresectable Stage III NSCLC, metastatic NSCLC, extensive-stage SCLC, and biliary tract cancer. It also treats unresectable HCC in combination with IMJUDO. TROPION-Lung01 and NeoCOAST-2 are Phase III and II trials evaluating datopotamab deruxtecan and IMFINZI, respectively, in lung cancer. AstraZeneca collaborates with Daiichi Sankyo for ADC development and aims to improve lung cancer outcomes.
Merck & Daiichi Sankyo's ifinatamab deruxtecan showed a 54.8% objective response rate in pretreated ES-SCLC patients, selected as optimal dose for ongoing trials.
I-DXd (ifinatamab deruxtecan) showed clinically meaningful responses in pretreated extensive-stage SCLC patients, with a confirmed response rate of 26.1% at 8 mg/kg and 54.8% at 12 mg/kg. The 12 mg/kg dose was selected as optimal for further study.
MSD and Daiichi Sankyo presented interim results from the Ideate-Lung01 trial at WCLC, showing the 12 mg/kg dose of ifinatamab deruxtecan (I-DXd) had a 54.8% overall response rate (ORR) in extensive-stage small cell lung cancer (SCLC) patients, with a disease control rate (DCR) of 90.5%. The higher dose also showed improved progression-free and overall survival. Safety concerns included interstitial lung disease and gastrointestinal toxicities, but no 'great surprises'. The companies have started phase 3 Ideate-Lung02 study.
Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% ORR at 12 mg/kg in pretreated ES-SCLC patients, selected as optimal dose for IDeate-Lung01 phase 2 trial extension and IDeate-Lung02 phase 3 study.
Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% objective response rate at 12 mg/kg in pretreated extensive-stage small cell lung cancer patients, leading to its selection for phase 2 and 3 trials.